Form 4 for PLX Protalix BioTherapeutics, Inc.
Accepted 2025-09-04 00:00:00 ET · period of report 2025-09-03 · accession 0001415889-25-023708 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-09-04 | 2025-09-03 | PLX | Forster Eliot | Dir | A - Grant | — | +7,500 | 7,500 | New | — |
| D | 2025-09-04 | 2025-09-03 | PLX | Forster Eliot | Dir | A - Grant | $0.00 | +15.0K | 15.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-03 | A | A | 7,500 | — | 7,500 | I By Trust | — | — | (F1) Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant. |
| 2 | Derivative | Stock Options (Right to Buy) | 2025-09-03 | A | A | 15,000 | $0.00 | 15,000 | D | $1.64 · — to 2035-09-03 | 15,000 Common Stock | (F3) Does not include options to purchase 85,715 shares of common stock at an exercise price equal to $1.75 per share that expire on September 14, 2033, (F2) The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. |